AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Anthony Fauci, President Joe Biden's chief medical advisor, again sought to reassure Americans that AstraZeneca's still-experimental COVID-19 vaccine is a strong candidate even though the drug maker reportedly miscommunicated findings from a clinical trial earlier this week.

Fauci insists that AstraZeneca's COVID-19 vaccine candidate is ‘good' after issue with information in company's press release

AstraZeneca will likely release a modified statement regarding its Covid-19 vaccine, White House Chief Medical Advisor Dr. Anthony Fauci said Wednesday.

Fauci says AstraZeneca will likely issue modified statement on Covid vaccine

Los Angeles, California--(Newsfile Corp. - March 24, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive...

MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

AstraZeneca's data misstep is just the latest example in a series of blunders by the company that could impact people's willingness to take the vaccine.

AstraZeneca missteps threaten to further erode trust in Covid vaccine as company seeks U.S. approval

BioNTech SE

Johnson & Johnson

Moderna

Novavax

Pfizer

Viatris

This question has multiple right answers.

Which COVID Vaccine Stock Is the Best Pick?

NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AstraZeneca plc ("AstraZeneca" or the "Company") (NASDAQ: AZN) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-00825, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise, acquired AstraZeneca securities between May 21, 2020 and November 20, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AstraZeneca plc of Class Action Lawsuit and Upcoming Deadline - AZN

AstraZeneca has defended its use of coronavirus vaccine data after US authorities suggested some results from a large American-led trial may have been based on "outdated information".

AstraZeneca defends COVID vaccine trial data against US claims of possible 'outdated information'

LOS ANGELES--(BUSINESS WIRE)---- $AZN #AZN--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AstraZeneca PLC

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AstraZeneca PLC and Encourages Investors with Losses of $100,000 to Contact the Firm

Investors will have to wait for the final results from a U.S. based clinical trial.

AstraZeneca's Vaccine Data May Not Be as Good as It First Appeared

The consequences of being irrationally exuberant about the current state of the SARS-Co-V-2 pandemic has the potential to lead to much more than a financial downturn; it has the potential to lead to an unimaginable continued loss of life.

AstraZeneca, Data Collection, And Covid-19 Irrational Exuberance

White House Chief Medical Advisor Dr. Anthony Fauci has commented on the latest AstraZeneca plc (NASDAQ: AZN) coronavirus vaccine controversy, noting the company's Monday press release contains some falsehoods but that shouldn't take away from the efficacy of the vaccine.  The numbers published Monday were based on a pre-specified interim analysis with a Feb. 17 data cutoff, AstraZeneca said in a press release late Tuesday morning.

Fauci Reacts To AstraZeneca Coronavirus Data, Says British Vaccine Developer Made 'Unforced Error'

Snowflake

Snowflake Inc (NYSE: SNOW) shares are trading higher after UBS initiated coverage on the stock with a Buy rating and a price target of $275 per share. Snowflake is a data lake, warehousing, and sharing company that came public in 2020.

What's Happening With SNOW Stock And AZN Stock Tuesday?

The global case tally for the coronavirus-borne illness COVID-19 crept closer to 124 million on Tuesday, as U.S. health officials raised concerns about results from a trial of AstraZeneca PLC's vaccine less than a day after the data were released.

Coronavirus Update: Global case tally for COVID-19 nears 124 million as U.S. health experts question AstraZeneca trial data

In a rare public rebuke, the top US infectious disease doctor is criticizing the pharma company AstraZeneca for statements it recently made about its coronavirus vaccine. Dr. Anthony Fauci said on Tuesday that AstraZeneca's Monday press release about its COVID-19 vaccine "wasn't completely accurate."

'It wasn't completely accurate': Fauci criticizes AstraZeneca's COVID-shot disclosure, calling it an 'unforced error'

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AstraZeneca PLC (NASDAQ: AZN) resulting from allegations that AstraZeneca may have issued materially misleading business information to the investing public. SO WHAT: If you purchased AstraZeneca securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme

AZN BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages AstraZeneca PLC Investors to Inquire About Class Action Investigation – AZN

NIH's Data Safety Monitoring Board questions AstraZeneca's (AZN) COVID-19 vaccine data from its late-stage U.S. study.

AstraZeneca (AZN) COVID-19 Vaccine Data May Be Outdated Per NIH

AstraZeneca Plc's (NASDAQ: AZN) vaccine prospects were looking bright on Monday when the company reported its COVID-19 demonstrated 79% efficacy in Phase 3 U.S. trials. Then, sometime after midnight, U.S. officials took an unusual step of publicly questioning if that data was complete.

AstraZeneca Responds To NIAID Concerns Regarding COVID-19 Vaccine, Says Data As Of 17 Feb

AstraZeneca shares fell Tuesday after US health officials raised questions about the drug maker's COVID-19 vaccine, saying the company may have used some outdated trial data in its update about the formula. The Data and Safety Monitoring Board, an independent expert panel that monitors trial safety, said in a statement early Tuesday it was concerned that information released by AstraZeneca about its COVID-19 vaccine clinical trial "may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data."

AstraZeneca slips after independent data monitor questions potential use of 'outdated' data for vaccine trial (AZN)

Interim data from a U.S. late-stage study on AstraZeneca's (AZN) COVID-19 vaccine shows that the candidate was, on average, about 79% effective in preventing COVID-19.

Will the Fourth COVID-19 Vaccine in U.S. Get FDA Nod Soon?

AstraZeneca faces hurdles before entering the U.S. market.

Could These 2 Challenges Derail the AstraZeneca Vaccine?

The latest news could have a bigger impact in the rest of the world than in the U.S.

U.S. doubts hit AstraZeneca COVID-19 vaccine just as Europe resumes its rollout

Hello, Welcome to Insider Healthcare. I'm Blake Dodge, and I cover Big Tech for the healthcare team at Insider. Here's today's news:

AstraZeneca's latest COVID-19 vaccine setback

NIAID is headed by U.S. infectious diseases expert Dr. Anthony Fauci and is part of the National Institutes of Health.

AstraZeneca May Have Included ‘Outdated Information' in Vaccine Trial, NIAID Says

AstraZeneca may have used partially-outdated data when it reported promising US trial results on Monday, the US National Institute of Allergy and Infectious Diseases (NIAID) has said. An independent expert panel that monitors trial safety was "concerned" that the information released by AstraZeneca was "outdated," which may have provided "an incomplete view of the efficacy data," the NIAID said late Monday night, in a highly unusual statement.

AstraZeneca may have used outdated data in its US vaccine trial results, giving an 'incomplete view' of how well the shot worked, officials said

AstraZeneca Plc (NYSE: AZN) may have included outdated data related to the U.S. trials of its COVID-19 vaccine that resulted in an incomplete view of the efficacy data, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) said on Monday. What Happened: The British drugmaker had said earlier that interim data from U.S. clinical trials in over 32,000 people shows its COVID-19 vaccine developed with Oxford University is 79% effective and safe.

News for AstraZeneca Stock (AZN)